Date | Time | Source | Announcement |
---|---|---|---|
09 Feb 2006 | 07:00 AM | USD5m Idenix Collaboration | |
26 Jan 2006 | 07:00 AM | Collaboration with UCB | |
19 Jan 2006 | 07:00 AM | H.Lundbeck A/S Collaboration | |
17 Jan 2006 | 07:00 AM | Collaboration with Organon | |
12 Jan 2006 | 07:00 AM | Bcl-2 added to Crystal Bank | |
10 Jan 2006 | 07:00 AM | Collaborative Agreement | |
05 Jan 2006 | 07:00 AM | Trading Update | |
13 Dec 2005 | 07:00 AM | Collaborative Agreement | |
24 Nov 2005 | 07:00 AM | Crystal Bank Developments | |
09 Nov 2005 | 08:48 AM | Holding(s) in Company | |
07 Nov 2005 | 11:02 AM | Result of AGM | |
27 Oct 2005 | 07:00 AM | Collaboration with Schering | |
10 Oct 2005 | 12:59 PM | Annual Report and Accounts | |
22 Sep 2005 | 07:00 AM | Cancer Therapy Deal | |
19 Sep 2005 | 07:00 AM | Preliminary Results | |
01 Sep 2005 | 07:00 AM | Launch of Crystal Bank | |
10 Aug 2005 | 07:00 AM | Deal with Spanish Pharma | |
01 Aug 2005 | 09:30 AM | Holding(s) in Company | |
29 Jul 2005 | 03:32 PM | Holding(s) in Company | |
25 Jul 2005 | 07:00 AM | Major Drug Collaboration | |
30 Jun 2005 | 07:00 AM | Success Milestone | |
13 May 2005 | 07:00 AM | First UK Installation | |
25 Apr 2005 | 12:59 PM | Offer discussions terminated | |
11 Apr 2005 | 07:00 AM | Contract Extension | |
29 Mar 2005 | 07:00 AM | Interim Results | |
07 Mar 2005 | 12:01 PM | Rule 8 - Sareum Holdings plc | |
07 Mar 2005 | 07:00 AM | Rule 2.10 Announcement | |
04 Mar 2005 | 07:00 AM | Statement re speculation | |
15 Dec 2004 | 07:00 AM | Collaboration | |
06 Dec 2004 | 07:00 AM | New Cancer Collaboration | |
03 Dec 2004 | 04:14 PM | Shareholding | |
01 Dec 2004 | 07:00 AM | Drug Discovery Collaboration | |
29 Nov 2004 | 02:13 PM | Holding(s) in Company | |
22 Nov 2004 | 07:00 AM | Collaboration Agreement | |
15 Nov 2004 | 11:56 AM | Holding(s) in Company | |
09 Nov 2004 | 07:00 AM | Collaborative Agreement | |
26 Oct 2004 | 05:29 PM | Holding(s) in Company | |
11 Oct 2004 | 07:00 AM | First day of dealings on AIM |
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.
The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
SAR share price listed on AIM in 2004 under the ticker SAR.